CoreMedic Secures $42M to Revolutionize Minimally Invasive Mitral Valve Repair with ChordArt

CoreMedic is thrilled to announce a major milestone in its journey to revolutionize heart valve care, having successfully raised 42,000,000 in new funding. This significant capital injection underlines the strong confidence investors have in CoreMedic’s mission and innovative approach to addressing one of the most critical challenges in global healthcare—heart valve diseases. As a privately held medical device company headquartered in Radolfzell, Germany, with a key subsidiary in Biel/Bienne, Switzerland, CoreMedic is steadfast in its commitment to enhancing the quality of life for patients worldwide. The newly secured funds will accelerate the development and clinical evaluation of its flagship product, ChordArt™, a transfemoral system designed for mitral valve chordal repair in the beating heart. Distinguished by its less invasive nature compared to traditional open-chest or trans-apical surgical methods, ChordArt™ represents a groundbreaking first-line therapy option for patients suffering from mitral valve dysfunction. By allowing a broader patient population to access mitral valve repair, CoreMedic is setting a new standard for treatment efficacy and patient comfort. The investment will be pivotal in optimizing the technology behind ChordArt™, expediting current clinical trials in European clinics, and ultimately facilitating its wider adoption in clinical practice. With its EN ISO 13485 certification, CoreMedic exemplifies rigorous quality standards and regulatory compliance, further solidifying its reputation as a trusted innovator in the medical device industry. This funding milestone is a testament to the company’s vision and the immense potential of its therapeutic solutions, paving the way for improved patient outcomes and a brighter future in heart valve care. For further information about CoreMedic and its innovative solutions, please visit www.coremedic.ch.